Embracing Innovation to Fight the Good Fight: Lowering the Costs of Viral Vector Manufacture

At Advanced Therapies Week 2025, ProteoNic highlighted its approach to reducing viral vector manufacturing costs, a major barrier to broad patient access in cell and gene therapy. In this AT-TV session, Shalinee Khadun, Director of Business Development, speaks with Benjamin McLeod of Convey Bio about the company’s proprietary 2G UNic® technology, which includes a series of optimized promoters and enhancers designed to boost vector titers across multiple platforms, including AAV and lentiviral vectors.

With the high costs of manufacturing continuing to challenge the scalability of advanced therapies, ProteoNic’s technology addresses a critical need by increasing yields. This helps lower overall production costs, providing a path toward more affordable treatments.

The discussion also touches on broader industry challenges, including staffing shortages, supply chain complexities, and the need for specialized expertise. Shalinee Khadun emphasizes that collaboration across technology providers, CDMOs, and therapy developers is essential to achieving sustainable cost reductions and advancing the field collectively.

ProteoNic’s flexible, royalty-free licensing model underscores their commitment to open collaboration, ensuring that partners can integrate these yield-enhancing tools without restrictive commercial terms.

Looking ahead, Shalinee Khadun envisions a future where cost reductions, improved workforce conditions, and greater industry collaboration converge to make cell and gene therapies more viable and accessible for patients worldwide.